Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i> –Induced B-Cell Acute Lymphoblastic LeukemiaLinyu Yang, Lijuan Chen, Liya Luo et al.|Clinical Cancer Research|2019Cited by 19